Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Phase 2
Completed
- Conditions
- Risk for Colorectal Cancer
- Interventions
- Biological: MUC1 - Poly ICLC
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Robert Schoen
- Target Recruit Count
- 46
- Registration Number
- NCT00773097
- Locations
- 🇺🇸
Digestive Disorders Clinic, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath